Footnotes

• Contributors NR drafted the first version, which was subsequently revised by HIB, DJL and AM.

• Competing interests NR has received grants from BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer, Sobi during the conduct of the study, and personal fees and speaker honorarium from AbbVie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Celgene, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, R-Pharm, Roche, Sanofi, Servier and Takeda. HIB reports grants/research support from National Institutes of Health, NIAMS; HIB has also received consultancy fees from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, Janssen; speaker bureaus from Genentech. DJL reports grants/research support from National Institutes of Health, NIAMS; DJL has also received consultancy fees from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, Janssen, and speaker bureaus from Genentech. Starting 1 March 2016 AM became the Scientific Director of the G Gaslini Hospital; therefore his role does not allow to render private consultancies resulting in personal income. AM has performed consultancy activities on behalf of the Gaslini Institute for the following companies: AbbVie, Boehringer, Novartis and R-Pharm. The money received for these activities are directly transferred to the Gaslini Institute’s bank account.

• Provenance and peer review Commissioned; internally peer reviewed.